8 Independent prognostic factors for response: updated results of the ABCSG-24 study evaluating the addition of capecitabine to epirubicin-docetaxel neoadjuvant therapy for early breast cancer (EBC)

✍ Scribed by G.G. Steger; R. Greil; R. Jakesz; A. Lang; B. Mlineritsch; M. Rudas; C. Marth; H. Stoeger; C.F. Singer; M. Gnant

• Book ID: 119601026
• Publisher: Elsevier Science
• Year: 2010
• Tongue: English
• Weight: 47 KB
• Volume: 8
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(10)70040-9